7 August 2020 Malaysia Malaysia Wants To Extend Compulsory Licence For Hepatitis C Drug Remdesivir is not in the Malaysian treatment protocol for Covid-19, says Dr Adham Baba.
26 May 2020 Opinion What Is A Covid-19 Cure Worth? Compulsory licencing may not necessarily guarantee widespread access of remdesivir to Covid-19 patients in Malaysia.
22 May 2020 Letter There Is No Reason To Accept High Prices For Covid-19 Treatments — Mark Cheong Wall Street analysts suggest remdesivir could be priced between US5,000-US10,000 for a 10-day course of treatment.
13 November 2019 Malaysia Only 1pc Of Hepatitis C Patients Treated, Two Years After Malaysia Gets Generics Only over 50,000 high-risk people were screened this year, out of an estimated 500,000 Malaysians living with Hepatitis C.
27 May 2019 Malaysia New Drugs Delayed Five Years If Malaysia Violates IP Rights A US think tank warns Malaysia about compulsory licensing of Hepatitis C medicine, sofosbuvir, becoming a trade issue.